Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine

Suganthini Krishnan-Natesan, Pranatharthi H. Chandrasekar, Elias Kurian Manavathu, Sanjay G. Revankar

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aspergillus ustus infections are associated with a high mortality in immunocompromised hosts, and the mold has decreased susceptibility to most antifungal drugs, especially azoles. We report primary cutaneous A. ustus infection in a patient who failed itraconazole therapy and was switched to voriconazole (VRC). During VRC therapy, the MICs of VRC, amphotericin B (AMB), caspofungin (CFG), and terbinafine (TBF) were 4, 2, 64, and 0.13 μg/mL, respectively. Because the MIC to VRC was high, TBF was added to VRC for synergy based on anecdotal data from other mycoses. After treatment with VRC and TBF for 5 months, MICs of VRC, AMB, CFG, and TBF of A. ustus were 8, 1, 64, and 4 μg/mL respectively. Although the MICs of VRC and TBF increased during antifungal therapy, the patient responded well to the combination antifungal therapy with surgical debridement. With a successful outcome despite high MICs and with limited therapeutic options currently available, we investigated the in vitro activity of posaconazole (PCZ) and VRC individually and in combination with AMB, CFG, or TBF using the fractional inhibitory concentration index (FICI) method. Combination of VRC with TBF showed synergistic activity (FICI = 0.5). Therefore, combination of VRC and TBF with surgical debridement, when appropriate, may be a viable treatment option for refractory A. ustus infections.

Original languageEnglish (US)
Pages (from-to)443-446
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume62
Issue number4
DOIs
StatePublished - Dec 1 2008

Fingerprint

terbinafine
Debridement
Aspergillus
Skin
caspofungin
Infection
Amphotericin B
Therapeutics
Voriconazole

Keywords

  • Aspergillus ustus
  • Combination therapy
  • Cutaneous infection
  • Immunocompromised
  • Terbinafine
  • Voriconazole resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. / Krishnan-Natesan, Suganthini; Chandrasekar, Pranatharthi H.; Manavathu, Elias Kurian; Revankar, Sanjay G.

In: Diagnostic Microbiology and Infectious Disease, Vol. 62, No. 4, 01.12.2008, p. 443-446.

Research output: Contribution to journalArticle

Krishnan-Natesan, Suganthini ; Chandrasekar, Pranatharthi H. ; Manavathu, Elias Kurian ; Revankar, Sanjay G. / Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. In: Diagnostic Microbiology and Infectious Disease. 2008 ; Vol. 62, No. 4. pp. 443-446.
@article{5c59b171c9cb4e6d91c12fd62d78d5f5,
title = "Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine",
abstract = "Aspergillus ustus infections are associated with a high mortality in immunocompromised hosts, and the mold has decreased susceptibility to most antifungal drugs, especially azoles. We report primary cutaneous A. ustus infection in a patient who failed itraconazole therapy and was switched to voriconazole (VRC). During VRC therapy, the MICs of VRC, amphotericin B (AMB), caspofungin (CFG), and terbinafine (TBF) were 4, 2, 64, and 0.13 μg/mL, respectively. Because the MIC to VRC was high, TBF was added to VRC for synergy based on anecdotal data from other mycoses. After treatment with VRC and TBF for 5 months, MICs of VRC, AMB, CFG, and TBF of A. ustus were 8, 1, 64, and 4 μg/mL respectively. Although the MICs of VRC and TBF increased during antifungal therapy, the patient responded well to the combination antifungal therapy with surgical debridement. With a successful outcome despite high MICs and with limited therapeutic options currently available, we investigated the in vitro activity of posaconazole (PCZ) and VRC individually and in combination with AMB, CFG, or TBF using the fractional inhibitory concentration index (FICI) method. Combination of VRC with TBF showed synergistic activity (FICI = 0.5). Therefore, combination of VRC and TBF with surgical debridement, when appropriate, may be a viable treatment option for refractory A. ustus infections.",
keywords = "Aspergillus ustus, Combination therapy, Cutaneous infection, Immunocompromised, Terbinafine, Voriconazole resistance",
author = "Suganthini Krishnan-Natesan and Chandrasekar, {Pranatharthi H.} and Manavathu, {Elias Kurian} and Revankar, {Sanjay G.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.diagmicrobio.2008.08.003",
language = "English (US)",
volume = "62",
pages = "443--446",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine

AU - Krishnan-Natesan, Suganthini

AU - Chandrasekar, Pranatharthi H.

AU - Manavathu, Elias Kurian

AU - Revankar, Sanjay G.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Aspergillus ustus infections are associated with a high mortality in immunocompromised hosts, and the mold has decreased susceptibility to most antifungal drugs, especially azoles. We report primary cutaneous A. ustus infection in a patient who failed itraconazole therapy and was switched to voriconazole (VRC). During VRC therapy, the MICs of VRC, amphotericin B (AMB), caspofungin (CFG), and terbinafine (TBF) were 4, 2, 64, and 0.13 μg/mL, respectively. Because the MIC to VRC was high, TBF was added to VRC for synergy based on anecdotal data from other mycoses. After treatment with VRC and TBF for 5 months, MICs of VRC, AMB, CFG, and TBF of A. ustus were 8, 1, 64, and 4 μg/mL respectively. Although the MICs of VRC and TBF increased during antifungal therapy, the patient responded well to the combination antifungal therapy with surgical debridement. With a successful outcome despite high MICs and with limited therapeutic options currently available, we investigated the in vitro activity of posaconazole (PCZ) and VRC individually and in combination with AMB, CFG, or TBF using the fractional inhibitory concentration index (FICI) method. Combination of VRC with TBF showed synergistic activity (FICI = 0.5). Therefore, combination of VRC and TBF with surgical debridement, when appropriate, may be a viable treatment option for refractory A. ustus infections.

AB - Aspergillus ustus infections are associated with a high mortality in immunocompromised hosts, and the mold has decreased susceptibility to most antifungal drugs, especially azoles. We report primary cutaneous A. ustus infection in a patient who failed itraconazole therapy and was switched to voriconazole (VRC). During VRC therapy, the MICs of VRC, amphotericin B (AMB), caspofungin (CFG), and terbinafine (TBF) were 4, 2, 64, and 0.13 μg/mL, respectively. Because the MIC to VRC was high, TBF was added to VRC for synergy based on anecdotal data from other mycoses. After treatment with VRC and TBF for 5 months, MICs of VRC, AMB, CFG, and TBF of A. ustus were 8, 1, 64, and 4 μg/mL respectively. Although the MICs of VRC and TBF increased during antifungal therapy, the patient responded well to the combination antifungal therapy with surgical debridement. With a successful outcome despite high MICs and with limited therapeutic options currently available, we investigated the in vitro activity of posaconazole (PCZ) and VRC individually and in combination with AMB, CFG, or TBF using the fractional inhibitory concentration index (FICI) method. Combination of VRC with TBF showed synergistic activity (FICI = 0.5). Therefore, combination of VRC and TBF with surgical debridement, when appropriate, may be a viable treatment option for refractory A. ustus infections.

KW - Aspergillus ustus

KW - Combination therapy

KW - Cutaneous infection

KW - Immunocompromised

KW - Terbinafine

KW - Voriconazole resistance

UR - http://www.scopus.com/inward/record.url?scp=56049125932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049125932&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2008.08.003

DO - 10.1016/j.diagmicrobio.2008.08.003

M3 - Article

VL - 62

SP - 443

EP - 446

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -